The deal creates some immediate and long-term opportunities for Supernus, which focuses on central nervous system diseases.
NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN). Click here to learn more and participate in the action. On October 12, 2021, Adamas announc
WILMINGTON, Del., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Adamas Pharmaceuticals, Inc. (“Adamas”) (NASDAQ GM: ADMS) regarding possible breaches of fiduciary duties and other violations of law related to Adamas’ agreement to be acquired by Supernus Pharmaceuticals, Inc. (NASDAQ GM: SUPN). Under the terms of the agreement, Adamas’ shareholders will receive $8.10 in cash and two non-tradeable contingent value rights collectively worth up to $1.00 per